Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology

Loading news article.

Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology | WAPE

Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology

Article summary

Related companies

Comments —